Name | velagliflozin |
---|---|
Synonyms |
velagliflozin
(1S)-1,5-Anhydro-1-[4-cyano-3-(4-cyclopropylbenzyl)phenyl]-D-glucitol UNII:FV2YU8SL0P D-Glucitol, 1,5-anhydro-1-C-[4-cyano-3-[(4-cyclopropylphenyl)methyl]phenyl]-, (1S)- |
Description | Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity. |
---|---|
Related Catalog | |
Target |
SGLT2[1] |
In Vitro | Velagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity[1]. |
In Vivo | Velagliflozin (1 mg/kg, p.o.) increases cholesterol, albumin, beta-hydroxybutyrate (BHB), nonesterified fatty acids (NEFA), and urinary glucose excretion, and decreases respiratory exchange ratio in cats[1]. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 648.6±55.0 °C at 760 mmHg |
Molecular Formula | C23H25NO5 |
Molecular Weight | 395.448 |
Flash Point | 346.1±31.5 °C |
Exact Mass | 395.173279 |
LogP | 3.87 |
Vapour Pressure | 0.0±2.0 mmHg at 25°C |
Index of Refraction | 1.670 |
Storage condition | -20°C |